Experimental CAR T-Cell therapy targets Hard-to-Treat ovarian cancer
NCT ID NCT04670068
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment for women with recurrent epithelial ovarian cancer. The therapy uses the patient's own immune cells, modified to find and attack cancer cells that carry a protein called B7-H3. The main goal is to check safety and find the best dose, with up to 21 participants planned.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Metabolic clues: could your Body's energy use predict ovarian cancer outcomes?
- Can a custom vaccine train the body to fight ovarian cancer?
- Can a 'Smart Bomb' drug outsmart recurrent ovarian cancer?
- Can a targeted drug boost standard ovarian cancer therapy?
- Can heated chemo during surgery help older women with ovarian cancer?
- Can a daily pill keep BRCA-Linked ovarian cancer at bay?